Search results for: 'comparative distributed energy'

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

11 Nov 2015  |  Asia Pacific  |  Market Research

Asia-Pacific Point-of-Care Testing Market

Trends, Challenges, and Best Practices for Stakeholders

Infographics

×

Asia-Pacific (APAC) point-of-care testing (POCT) market was worth $2.80 billion in 2014. In hospitals, POC is used more in emergency rooms (ERs), operation theatres (OTs), recovery rooms (RRs), cath labs, and intensive care units (ICU). The rental model in which the cost of the device is borne by the manufacturer while the profit is shared by the h...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

This research service provides an analysis for the healthcare market in Vietnam. In addition to an overview of the total healthcare market, it presents detailed analyses of current trends, market sizes, revenue forecasts, and drivers and restraints for the hospital (private and public) market, and for the manufacturing and distribution of medical d...

Healthcare expenditure in Singapore is expected to grow, fueled by factors such as rising incomes and a progressively aging population. Diagnostics has emerged as a way for earlier and better identification of diseases to control rising healthcare costs in Singapore. Hence, the country has become a natural choice for many global diagnostic companie...